Association of Lower Exposure Risk With Paucisymptomatic/Asymptomatic Infection, Less Severe Disease, and Unrecognized Ebola Virus Disease: A Seroepidemiological Study.
Association of Lower Exposure Risk With Paucisymptomatic/Asymptomatic Infection, Less Severe Disease, and Unrecognized Ebola Virus Disease: A Seroepidemiological Study.
复制标题
较低的暴露风险与症状/无症状感染，严重严重疾病和未识别的埃博拉病毒疾病的关联：一项血清ePIDEMIologicy研究。
DOI：
10.1093/ofid/ofac052
复制
发表时间：
2022-04
影响因子：
4.2
通讯作者：
Richardson ET
中科院分区：
文献类型：
--
作者：
Kelly JD;Frankfurter RG;Tavs JM;Barrie MB;McGinnis T;Kamara M;Freeman A;Quiwah K;Davidson MC;Dighero-Kemp B;Gichini H;Elliott E;Reilly C;Hensley LE;Lane HC;Weiser SD;Porco TC;Rutherford GW;Richardson ET
目前尚不清楚埃博拉病毒（EBOV）暴露风险与疾病严重程度之间是否存在剂量依赖关系。2016年9月至2017年7月，我们对塞拉利昂科诺区几个传播链的埃博拉病毒病（EVD）病例和家庭接触者进行了一项横断面、基于社区的研究。我们分析了154个隔离家庭，包括报告的EVD病例及其密切接触者。我们使用流行病学调查和血液样本将疾病严重程度定义为无感染、少量/无症状感染、未识别的EVD、报告的EVD存活病例或报告的EVD死亡病例。我们用丝状病毒动物非临床组EBOV糖蛋白免疫球蛋白G抗体试验确定血清阳性。我们从8个问题中定义了暴露风险水平，并将与体液接触视为最大暴露风险。我们的分析包括76例报告的EVD病例（包括死亡者和幸存者）和421例密切接触者。在这些接触者中，40人血清学阳性（22人为少症状，18人未被识别），占全部116例EBOV感染的34%。较高的暴露风险与EBOV感染（最大风险：调整后的比值比[AOR]，12.1 [95%置信区间{CI}，5.8-25.4;趋势检验：P <.001）和更严重的疾病（最大风险：AOR，25.2 [95% CI，6.2-102.4];趋势检验：P <.001）相关。 这项以社区为基础的EVD病例和接触者研究提供了暴露风险与疾病严重程度之间存在剂量依赖关系的流行病学证据，这可能部分解释了为什么会发生少量/无症状EBOV感染、较轻疾病和未被识别的EVD。这项以社区为基础的埃博拉病毒病（EVD）病例和接触者研究提供了暴露风险与疾病严重程度之间剂量依赖关系的流行病学证据，这可能部分解释了为什么会发生罕见/无症状埃博拉病毒感染、不太严重的疾病和未被识别的EVD。
It remains unclear if there is a dose-dependent relationship between exposure risk to Ebola virus (EBOV) and severity of illness. From September 2016 to July 2017, we conducted a cross-sectional, community-based study of Ebola virus disease (EVD) cases and household contacts of several transmission chains in Kono District, Sierra Leone. We analyzed 154 quarantined households, comprising both reported EVD cases and their close contacts. We used epidemiological surveys and blood samples to define severity of illness as no infection, pauci-/asymptomatic infection, unrecognized EVD, reported EVD cases who survived, or reported EVD decedents. We determine seropositivity with the Filovirus Animal Nonclinical Group EBOV glycoprotein immunoglobulin G antibody test. We defined levels of exposure risk from 8 questions and considered contact with body fluid as maximum exposure risk. Our analysis included 76 reported EVD cases (both decedents and survivors) and 421 close contacts. Among these contacts, 40 were seropositive (22 paucisymptomatic and 18 unrecognized EVD), accounting for 34% of the total 116 EBOV infections. Higher exposure risks were associated with having had EBOV infection (maximum risk: adjusted odds ratio [AOR], 12.1 [95% confidence interval {CI}, 5.8–25.4; trend test: P < .001) and more severe illness (maximum risk: AOR, 25.2 [95% CI, 6.2–102.4]; trend test: P < .001). This community-based study of EVD cases and contacts provides epidemiological evidence of a dose-dependent relationship between exposure risk and severity of illness, which may partially explain why pauci-/asymptomatic EBOV infection, less severe disease, and unrecognized EVD occurs. This community-based study of Ebola virus disease (EVD) cases and contacts provides epidemiological evidence of a dose-dependent relationship between exposure risk and severity of illness, which may partially explain why pauci-/asymptomatic Ebola virus infection, less severe disease, and unrecognized EVD occurs.
登录
查看更多内容
影响因子：
3.8
作者：
Richardson ET;Kelly JD;Barrie MB;Mesman AW;Karku S;Quiwa K;Marsh RH;Koedoyoma S;Daboh F;Barron KP;Grady M;Tucker E;Dierberg KL;Rutherford GW;Barry M;Jones JH;Murray MB;Farmer PE
通讯作者：
Farmer PE
影响因子：
6.4
作者：
Kelly, J. Daniel;Barrie, Mohamed Bailor;Richardson, Eugene T.
通讯作者：
Richardson, Eugene T.
影响因子：
56.3
作者：
Glynn, Judith R.;Bower, Hilary;Tedder, Richard S.
通讯作者：
Tedder, Richard S.
影响因子：
1.2
作者：
Camara, Ibrahima;Sow, Mamadou Saliou;Keita, Alpha Kabinet
通讯作者：
Keita, Alpha Kabinet
在塞拉利昂西部地区的埃博拉病毒疾病爆发期间接触追踪：未来的埃博拉疫情反应的教训。
影响因子：
5.2
作者：
Olu OO;Lamunu M;Nanyunja M;Dafae F;Samba T;Sempiira N;Kuti-George F;Abebe FZ;Sensasi B;Chimbaru A;Ganda L;Gausi K;Gilroy S;Mugume J
通讯作者：
Mugume J